From the FDA Drug Label
Renal Impairment: The Pharmacokinetic profiles of UROXATRAL 10 mg tablets in subjects with normal renal function (CLCR>80 mL/min), mild impairment (CLCR 60 to 80 mL/min), moderate impairment (CLCR 30 to 59 mL/min), and severe impairment (CLCR less than 30 mL/min) were compared. The mean Cmax and AUC values were increased by approximately 50% in patients with mild, moderate, or severe renal impairment [see Warnings and Precautions (5.2) and Use in Specific Populations (8. 6)].
Individuals with an estimated glomerular filtration rate (eGFR) greater than 60 can take alfuzosin, but they should be aware that the pharmacokinetic profiles of the drug may be affected, with increased Cmax and AUC values compared to those with normal renal function 1.
From the Research
Yes, individuals with an estimated glomerular filtration rate (eGFR) greater than 60 can generally take alfuzosin safely, as it is primarily metabolized by the liver and does not typically require dose adjustments for patients with normal to mildly impaired renal function. Alfuzosin is an alpha-blocker medication commonly prescribed for benign prostatic hyperplasia (BPH) to improve urinary symptoms. The standard dose of alfuzosin for adults is usually 10 mg once daily, as shown in studies such as 2, which demonstrated the efficacy and safety of alfuzosin 10 mg once daily for treating BPH over a 3-year period.
Key Points to Consider
- Alfuzosin is primarily metabolized by the liver, which supports its use in patients with normal to mildly impaired renal function, as indicated by an eGFR over 60 mL/min/1.73 m².
- The medication has been shown to improve urinary symptoms and quality of life in patients with BPH, with studies like 3 and 2 demonstrating its efficacy and safety.
- Individual factors can vary, and a healthcare provider should always be consulted before starting or changing any medication regimen to ensure it's appropriate for each patient's specific health situation.
- The most recent and highest quality study, 2, provides strong evidence for the use of alfuzosin in patients with BPH, including those with an eGFR greater than 60.
Important Considerations for Alfuzosin Use
- The medication is well-tolerated, with common adverse events including dizziness and ejaculatory disorders, as reported in studies such as 2.
- Changes in blood pressure are typically marginal, and the medication can be safely used in patients with hypertension, as shown in 2.
- Alfuzosin has been compared to other alpha-blockers, such as prazosin, and has been found to be at least as effective with a lower incidence of adverse events related to vasodilatory properties, as indicated in 4.